Fig. 2
From: Tempol improves neuroinflammation and delays motor dysfunction in a mouse model (SOD1G93A) of ALS
Behavioral analysis and survival. Tempol treatment delayed body weigt loss (a) and improved motor performance in the Rotarod test (b) compared to SOD1G93A mice treated with vehicle or riluzole. Each point in the graphs represents the mean ± SEM. Data were analyzed by two-way ANOVA for repeated measures, followed by a post hoc Bonferroni test. Treatment with tempol showed no significant change in survival (c) compared to SOD1G93A mice treated with vehicle. The results were evaluated with the log-rank test p = 0.5088. *** vs NTG, ### vs vehicle (p < 0.0001); && vs riluzole (p < 0.001)